Firstly, we determined whether the MDM2 inhibitor idasanutlin depends on wildtype p53 for its activity in ALL using an isogenic relapsed NALM6 cell line model with wildtype and monoallelic/biallelic TP53 deletion (Supplementary Fig. S1A). The gene discussed is TP53; the disease is acute lymphoblastic leukemia.